BioCryst Pharmaceuticals Inc BCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BCRX is a good fit for your portfolio.
News
-
BioCryst to Report First Quarter 2024 Financial Results on May 6
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
BioCryst to Present at Upcoming Investor Conferences
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
-
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment
-
BioCryst to Present at Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $4.15
- Day Range
- $4.15–4.30
- 52-Week Range
- $4.04–9.05
- Bid/Ask
- $4.19 / $4.20
- Market Cap
- $865.83 Mil
- Volume/Avg
- 608,672 / 3.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.41
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 531
- Website
- https://www.biocryst.com
Comparables
Valuation
|
Metric
|
BCRX
|
ENTA
|
AVIR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.36 | 0.56 |
Price/Sales | 2.41 | 3.53 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
BCRX
ENTA
AVIR
Financial Strength
|
Metric
|
BCRX
|
ENTA
|
AVIR
|
|---|---|---|---|
Quick Ratio | 2.97 | 6.04 | 17.86 |
Current Ratio | 3.31 | 6.25 | 18.24 |
Interest Coverage | −1.24 | — | — |
Quick Ratio
BCRX
ENTA
AVIR
Profitability
|
Metric
|
BCRX
|
ENTA
|
AVIR
|
|---|---|---|---|
Return on Assets (Normalized) | −36.54% | −27.96% | −15.46% |
Return on Equity (Normalized) | — | −47.34% | −16.16% |
Return on Invested Capital (Normalized) | −28.13% | −44.45% | −19.92% |
Return on Assets
BCRX
ENTA
AVIR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wqptzpkl | Ntzbb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Twyntshp | Fsxnwy | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hnsjydwgz | Vntcpzk | $97.8 Bil | |
MRNA
| Moderna Inc | Swysctm | Hnmfm | $41.3 Bil | |
ARGX
| argenx SE ADR | Nymcxcsdm | Zpjy | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vmzbcgdb | Ltqp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yzjzfyvd | Wybtms | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fnzxdqcdc | Jzjfll | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kyckflgl | Whllmr | $12.5 Bil | |
INCY
| Incyte Corp | Bhdkgkvrn | Vyyjnc | $11.6 Bil |